Gynecologic Cancers

P=N/A, N=45, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026

Non-response to the combination treatment is not characterized by immune inactivity but rather associated with sustained and coordinated increases in both activation and regulatory immune features, suggesting a shift toward systemic immune imbalance following treatment. These findings support the need for longitudinal, integrative immune monitoring strategies in future clinical trials.

Radiomics, which involves extracting high-dimensional features from medical images, has shown promise in differentiating between benign and malignant tumors, predicting genetic mutations (e.g., BRCA), and assessing tumor heterogeneity. Artificial intelligence (AI) models, particularly deep learning (DL) algorithms, have demonstrated high accuracy in diagnosing OC and predicting patient outcomes, often outperforming traditional methods.

High-risk patients exhibited diminished immune scores, enrichment of immunosuppressive populations including regulatory T cells and M2 macrophages, and inferior clinical outcomes. Our findings establish LDCD as a functionally important mechanism in cervical cancer at single-cell resolution and demonstrate the translational utility of integrating scRNA-seq with machine learning for the discovery of novel prognostic biomarkers and therapeutic targets.

The strongest expression in dVIN-associated VSCC highlights a possible link between aggressive tumor behavior and PRAME. dVIN-associated lesions may therefore represent promising candidates for PRAME-targeted therapy.

Elevated oxidative burden was associated with caspase-3 activation and concentration-dependent suppression of ERK1/2 phosphorylation, both of which were attenuated by N-acetylcysteine (NAC) co-treatment...Notably, NAC co-treatment partly restored p-ERK1/2 levels under the IC50 condition (P<0.01 vs. D-salicin alone), supporting a redox-linked contribution to ERK pathway modulation. Collectively, these findings indicated that D-salicin exerts selective anticancer effects in endometrial cancer cells by inducing oxidative stress and disrupting ERK1/2-mediated survival signaling, with NAC-sensitive modulation consistent with involvement of a redox-responsive ROS-ERK axis.

Furthermore, systemic factors such as insurance status, racial and socioeconomic disparities, access to care, and structural barriers to screening will also be explored. Collectively, this review emphasizes the need for the integration of molecular diagnostics with equitable screening and healthcare delivery to reduce diagnostic delays in cervical cancer within the United States to ultimately improve risk-specific treatment and clinical outcomes.

P=N/A, N=10000, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

A disparity exists not only in genetic testing availability but also clinic attendance between the public and private healthcare systems, which likely limits the ability to diagnose hereditary cancer syndromes associated with gynaecological cancers in public healthcare hospitals.

Furthermore, we uncovered widespread translational dysregulation in OCCC, with experimental validation confirming the pro-tumorigenic role of translationally upregulated RBM4. This study bridges a critical gap between genomic, transcriptomic, and proteomic landscapes in OCCC, offering valuable mechanistic insights into its pathogenesis.

We identified BRCA gene mutations in 38.6% of our patients. Most comparisons revealed no significant differences between BRCA-positive and BRCA-negative patients, highlighting the need for additional studies to determine the prognostic and clinical value of gene testing in EOC.

She was treated with a methylprednisolone taper, budesonide and infliximab, resulting in resolution of symptoms. In this case, colitis was successfully managed with corticosteroids and infliximab, allowing for safe re-challenge at a reduced dose. This case highlights the importance of recognizing and managing rare toxicities associated with antibody-drug conjugates to optimize their safe use in ovarian cancer treatment.